Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AAR

- PMLiVE

AstraZeneca chief on Brexit: “It’s going to be really painful”

Soriot also claims to be lowest paid CEO in sector

- PMLiVE

Labour party divided on Brexit ‘People’s Vote’

Growing support for second referendum being resisted by party leaders

- PMLiVE

CRUK forges £30m ‘post-Brexit’ R&D alliance

Joins forces with organisations in Italy and Spain

- PMLiVE

Health secretary’s ‘rip off’ remarks anger UK pharma

Row with Vertex has tainted government-industry relations

AstraZeneca AZ

AZ, Amgen’s first-in-class asthma drug gets breakthrough status

Clinical data from the TSLP targeting antibody is due in 2020

Sanofi reception

Sanofi gets EU OK for Ablynx flagship drug Cablivi

EMA clears the drug to treat adults with aTTP

- PMLiVE

MHRA cut out of regulatory work as Brexit looms

This year the regulatory body was only awarded two contracts to serve as the lead assessor on NDAs

- PMLiVE

Daily Brief: Blincyto another option in ALL alongside Kymriah, AZ approval for Bydureon

European approvals for Amgen and AstraZeneca

- PMLiVE

Brexit medicine stockpiling could cost £2bn

Cost will be incurred whether a 'no deal' Brexit is avoided or not

- PMLiVE

UK says firms should stockpile drugs in case of no-deal Brexit

Government also confirms the MHRA will handle UK marketing applications for new medicines

The European Medicines Agency: PRIME’d for access?

Leela Barham examines the impact of the EMA's PRIME fast track system after two years

- PMLiVE

Confidence in UK’s post-Brexit healthcare sector on the wane

Only 37% of healthcare workers agree that the UK would be an attractive destination after EU departure

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links